Protagonist Therapeutics, Inc. (NASDAQ:PTGX - Get Free Report) CFO Asif Ali sold 24,903 shares of Protagonist Therapeutics stock in a transaction dated Wednesday, March 12th. The stock was sold at an average price of $58.73, for a total value of $1,462,553.19. Following the completion of the sale, the chief financial officer now directly owns 62,821 shares of the company's stock, valued at approximately $3,689,477.33. This trade represents a 28.39 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website.
Protagonist Therapeutics Trading Down 0.2 %
Shares of PTGX opened at $54.78 on Friday. The company has a market cap of $3.36 billion, a PE ratio of 20.59 and a beta of 2.34. The stock has a 50-day moving average price of $39.63 and a 200-day moving average price of $42.24. Protagonist Therapeutics, Inc. has a 12-month low of $24.22 and a 12-month high of $60.60.
Protagonist Therapeutics (NASDAQ:PTGX - Get Free Report) last issued its quarterly earnings results on Friday, February 21st. The company reported $1.98 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.09) by $2.07. The firm had revenue of $170.64 million during the quarter, compared to the consensus estimate of $56.65 million. Protagonist Therapeutics had a return on equity of 34.68% and a net margin of 52.76%. As a group, analysts predict that Protagonist Therapeutics, Inc. will post 2.43 earnings per share for the current year.
Analysts Set New Price Targets
Several brokerages recently weighed in on PTGX. Truist Financial lifted their price objective on Protagonist Therapeutics from $60.00 to $76.00 and gave the stock a "buy" rating in a report on Tuesday. The Goldman Sachs Group decreased their price objective on Protagonist Therapeutics from $43.00 to $38.00 and set a "neutral" rating for the company in a report on Monday, February 24th. JPMorgan Chase & Co. lifted their price objective on Protagonist Therapeutics from $53.00 to $57.00 and gave the stock an "overweight" rating in a report on Tuesday, March 4th. HC Wainwright reaffirmed a "buy" rating and set a $54.00 target price on shares of Protagonist Therapeutics in a report on Monday, March 10th. Finally, JMP Securities reaffirmed a "market outperform" rating and set a $58.00 target price on shares of Protagonist Therapeutics in a report on Friday, February 7th. Two analysts have rated the stock with a hold rating, seven have given a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and a consensus price target of $61.22.
Read Our Latest Analysis on PTGX
Institutional Trading of Protagonist Therapeutics
A number of large investors have recently modified their holdings of PTGX. FNY Investment Advisers LLC bought a new stake in Protagonist Therapeutics in the 4th quarter worth approximately $38,000. GF Fund Management CO. LTD. bought a new stake in Protagonist Therapeutics in the 4th quarter worth approximately $48,000. Covestor Ltd lifted its position in Protagonist Therapeutics by 5,200.0% in the 4th quarter. Covestor Ltd now owns 1,643 shares of the company's stock worth $63,000 after buying an additional 1,612 shares during the last quarter. Harvest Fund Management Co. Ltd bought a new stake in Protagonist Therapeutics in the 3rd quarter worth approximately $69,000. Finally, KBC Group NV lifted its position in Protagonist Therapeutics by 54.4% in the 4th quarter. KBC Group NV now owns 2,093 shares of the company's stock worth $81,000 after buying an additional 737 shares during the last quarter. Institutional investors own 98.63% of the company's stock.
Protagonist Therapeutics Company Profile
(
Get Free Report)
Protagonist Therapeutics, Inc, a biopharmaceutical company, develops peptide-based drugs for hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing Rusfertide (PTG-300), an injectable hepcidin mimetic that completed phase 2 clinical trials for the treatment of polycythemia vera and other blood disorders; and JNJ-2113, an orally delivered investigational drug to block biological pathways that completed phase 2b clinical trials for the treatment of moderate-to-severe plaque psoriasis; and PN-943, an orally delivered, gut-restricted alpha 4 beta 7 specific integrin antagonist completed a phase 2 clinical trials in patients with moderate to severe ulcerative colitis.
Further Reading
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to contact@insidertrades.com.
